Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | OS2966 |
Synonyms | |
Therapy Description |
OS2966 is a monoclonal antibody that targets CD29, the integrin receptor beta-1 subunit, potentially leading to decreased tumor cell migration and proliferation, and reduced tumor growth (PMID: 23644530). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
OS2966 | OS-2966|OS 2966 | OS2966 is a monoclonal antibody that targets CD29, the integrin receptor beta-1 subunit, potentially leading to decreased tumor cell migration and proliferation, and reduced tumor growth (PMID: 23644530). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04608812 | Phase I | OS2966 | Convection-enhanced Delivery of OS2966 for Patients With High-grade Glioma Undergoing a Surgical Resection | Terminated | USA | 0 |